Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
L. Shulman, C. Cirrincione, D. Berry, et al.. (2012). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 88 times. https://doi.org/10.1200/JCO.2011.40.6405
Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
